中华检验医学杂志
中華檢驗醫學雜誌
중화검험의학잡지
CHINESE JOURNAL OF LABORATORY MEDICINE
2012年
7期
630-633
,共4页
惠威%郭新会%严艳%修冰水%张贺秋%李卓
惠威%郭新會%嚴豔%脩冰水%張賀鞦%李卓
혜위%곽신회%엄염%수빙수%장하추%리탁
肝炎病毒,丙型%第一高变区%交叉反应性%准种%抗病毒治疗
肝炎病毒,丙型%第一高變區%交扠反應性%準種%抗病毒治療
간염병독,병형%제일고변구%교차반응성%준충%항병독치료
Hepatitis C virus%Hypervariable region 1%Cross-reactivity%Quasipecies%Antiviral therapy
目的 探讨慢性丙型肝炎患者血清第一高变区( HVR1)抗体的交叉反应性与抗病毒治疗早期病毒应答(EVR)的关系.方法 用ELISA丙型肝炎病毒(HCV)HVR1抗体交叉反应性矩阵试剂检测抗HCV高变区抗体差异性,16条高变区抗原与患者血清交叉反应性比较采用Fisher精确概率检验.同时对2009年1月至12月首都医科大学附属北京佑安医院46例慢性丙型肝炎患者抗病毒治疗前基线血清标本进行分析.用荧光定量逆转录(RT)-PCR检测46例患者在治疗前、聚乙二醇干扰素联合利巴韦林治疗12周、48周的血清HCV RNA水平,并进行基因分型.结果 46例慢性丙型肝炎患者中,HCV2a型16例,1b型30例；治疗12周及结束时分别检测HCV RNA,其中,EVR组33例,非EVR组13例；2a型EVR发生率[93.8％ (15/16)]高于1b型[60.0％( 18/30),x2=4.316,P＜0.05].HCV 1b型慢性丙型肝炎患者中,EVR组平均多靶点HVR1抗原阳性反应数目为(12±4)个,明显高于非EVR组[(7±5)个,t=2.797,P＜0.01].经Fisher精确概率法检验,HVR1抗原编号分别为001、003、009、013、016的5条抗原在EVR组患者基线血清的反应阳性率明显高于非EVR组(P均＜0.05).结论 HVR1抗体的交叉反应性可能是一项抗病毒治疗疗效的预测指标.
目的 探討慢性丙型肝炎患者血清第一高變區( HVR1)抗體的交扠反應性與抗病毒治療早期病毒應答(EVR)的關繫.方法 用ELISA丙型肝炎病毒(HCV)HVR1抗體交扠反應性矩陣試劑檢測抗HCV高變區抗體差異性,16條高變區抗原與患者血清交扠反應性比較採用Fisher精確概率檢驗.同時對2009年1月至12月首都醫科大學附屬北京祐安醫院46例慢性丙型肝炎患者抗病毒治療前基線血清標本進行分析.用熒光定量逆轉錄(RT)-PCR檢測46例患者在治療前、聚乙二醇榦擾素聯閤利巴韋林治療12週、48週的血清HCV RNA水平,併進行基因分型.結果 46例慢性丙型肝炎患者中,HCV2a型16例,1b型30例；治療12週及結束時分彆檢測HCV RNA,其中,EVR組33例,非EVR組13例；2a型EVR髮生率[93.8％ (15/16)]高于1b型[60.0％( 18/30),x2=4.316,P＜0.05].HCV 1b型慢性丙型肝炎患者中,EVR組平均多靶點HVR1抗原暘性反應數目為(12±4)箇,明顯高于非EVR組[(7±5)箇,t=2.797,P＜0.01].經Fisher精確概率法檢驗,HVR1抗原編號分彆為001、003、009、013、016的5條抗原在EVR組患者基線血清的反應暘性率明顯高于非EVR組(P均＜0.05).結論 HVR1抗體的交扠反應性可能是一項抗病毒治療療效的預測指標.
목적 탐토만성병형간염환자혈청제일고변구( HVR1)항체적교차반응성여항병독치료조기병독응답(EVR)적관계.방법 용ELISA병형간염병독(HCV)HVR1항체교차반응성구진시제검측항HCV고변구항체차이성,16조고변구항원여환자혈청교차반응성비교채용Fisher정학개솔검험.동시대2009년1월지12월수도의과대학부속북경우안의원46례만성병형간염환자항병독치료전기선혈청표본진행분석.용형광정량역전록(RT)-PCR검측46례환자재치료전、취을이순간우소연합리파위림치료12주、48주적혈청HCV RNA수평,병진행기인분형.결과 46례만성병형간염환자중,HCV2a형16례,1b형30례；치료12주급결속시분별검측HCV RNA,기중,EVR조33례,비EVR조13례；2a형EVR발생솔[93.8％ (15/16)]고우1b형[60.0％( 18/30),x2=4.316,P＜0.05].HCV 1b형만성병형간염환자중,EVR조평균다파점HVR1항원양성반응수목위(12±4)개,명현고우비EVR조[(7±5)개,t=2.797,P＜0.01].경Fisher정학개솔법검험,HVR1항원편호분별위001、003、009、013、016적5조항원재EVR조환자기선혈청적반응양성솔명현고우비EVR조(P균＜0.05).결론 HVR1항체적교차반응성가능시일항항병독치료료효적예측지표.
Objective To discuss the relationship between the cross-reactivity of antibody against the hypervariable region 1 ( HVR1 ) of hepatitis C virus and early viral response ( EVR ) in patients undergoing antiviral therapy.Methods By ELISA and HCV HVR1 antibody cross-reactivity matrix reagent,the differences of anti-HCV hypervariable region antibody were tested in baseline serum from 46 patients with chronic hepatitis C before antiviral therapy.HCV genotyping and HCV RNA were analyzed by RT-PCR method.The HCV RNA assay was done at three time points:before treatment,pegylated interferon in combination with ribavirin therapy for 12 and 48 weeks.Results In 46 cases of chronic hepatitis C patients,there were 16 cases with HCV 2a type,30 cases with l b and 33 patients obtained EVR.The EVR incidence of type 2a[ 93.8％ ( 15/16 ) ] was higher than that of type 1 b[ 60.0％ (18/30),x2 =4.316,P ＜ 0.05 ].In the EVR group of type 1b chronic hepatitis C patients,the positive number of average multi-target HVR1 antigen was ( 12 ± 4),which was significantly higher than that in the Non-EVR patients [ (7 ± 5 ),t =2.797,P ＜0.01 ].Bv the Fisher exact test,it was showed that patients'serum response to HVR1 antigens numbered 001,003,009,013,016 were higher in EVR group than those in non-EVR group,with statistically significant (P ＜ 0.05 ).Conclusion The cross-reactivity of HVR1 antibody may play an important role in predicting the effectiveness of antiviral therapy.
